SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 11.04 |
| Enterprise Value ($M) | 8.67 |
| Book Value ($M) | 5.11 |
| Book Value / Share | 0.28 |
| Price / Book | 2.16 |
| NCAV ($M) | 3.79 |
| NCAV / Share | 0.21 |
| Price / NCAV | 2.92 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.98 |
| Return on Assets (ROA) | -0.47 |
| Return on Equity (ROE) | -0.60 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.22 |
| Current Ratio | 3.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5.95 |
| Assets | 7.27 |
| Liabilities | 2.16 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 5.42 |
| Operating Income | -6.37 |
| Net Income | -5.98 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.36 |
| Cash from Investing | -0.12 |
| Cash from Financing | -0.08 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Granahan Investment Management Inc/ma | 3.14 | -51.28 | |
| 13G | Wasatch Advisors Inc |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 546,927 | 1,424,433 | 38.40 | |
| 252,671 | 976,448 | 25.88 | |
| 1,717,072 | 4,503,512 | 38.13 | |
| 899,607 | 3,795,188 | 23.70 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BFRI – Biofrontera Inc. | BGM – BGM Group Ltd. |
| BIVI – BioVie Inc. | BNTC – Benitec Biopharma Inc. |
| BOLT – Bolt Biotherapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io